<DOC>
	<DOCNO>NCT00124449</DOCNO>
	<brief_summary>The purpose study ass Abatacept give six month prevent rheumatoid arthritis ( RA ) patient risk development RA comparison placebo . High risk patient define positive laboratory test anti-cyclic citrullinated peptide ( anti-CCP2 ) .</brief_summary>
	<brief_title>Study Abatacept Versus Placebo Assess Prevention Rheumatoid Arthritis ( RA ) Adult Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis undifferentiated arthritis Clinical synovitis two joint At least one three criterion diagnosis RA ( 1987 ) . No prior disease modify antirheumatic drug ( DMARDs ) /biologics . Duration disease must 18 month less . Positive antibody cyclic citrullinated peptide . Women child bear potential unwilling unable use acceptable method avoid pregnancy . Active vasculitis major organ system . Severe recurrent bacterial infection . History cancer last five year except certain skin cancer . Herpes zoster resolve less 2 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>